7 research outputs found
La modellizzazione dell'inquinamento atmosferico in aree urbane su scala locale: un esempio di applicazione in un quartiere di Torino
No full textEnhancing energy awareness through the analysis of thermal energy consumption
No full textEnergy efficiency by means of reduction in wasteful energy consumption is a growing policy priority for many countries. Innovative systems should be designed to continuously monitor a smart city environment and provide all stakeholders the tools to improve energy efficiency. This paper presents the EDEN platform, designed to collect and analyze thermal energy consumption of residential and public building heating systems. EDEN is being deployed in a major Italian city and collects energy consumption measurements through an extensive smart metering grid involving thousands of buildings. EDEN also collects and analyzes indoor climate conditions, and user feedbacks, such as their thermal comfort perception, by means of an ad-hoc social network. Collected data are further enriched with temporal and spatial information at different abstraction levels and meteorological data available as an open source data set. Several technical Key Performance Indicators (KPIs) have been defined to inform users on their building thermal energy consumption, while user-friendly KPIs present energy savings or over-consumptions in an informative fashio
Differences among young adults, adults and elderly chronic myeloid leukemia patients
No full textAbstract
BACKGROUND:
The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage.
PATIENTS AND METHODS:
To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period.
RESULTS:
Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old) particularly for the frequency of splenomegaly (71%, 63% and 55%, P < 0.001), and the greater spleen size (median value: 4.5, 3.0 and 1.0 cm, P < 0.001). According to the EUTOS score, that is age-independent, high-risk patients were more frequent among YAs, than among adult and elderly patients (18%, 9% and 6%, P < 0.001). In tyrosine kinase inhibitors-treated patients, the rates of complete cytogenetic and major molecular response were lower in YAs, and the probability of transformation was higher (16%, 5% and 7%, P = 0.011).
CONCLUSIONS:
The characteristics of CML or the host response to leukemia differ with age. The knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome.
CLINICAL TRIAL NUMBERS:
NCT00510926, NCT00514488, NCT00769327, NCT00481052.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected]
Marine bioprospecting - Trawling for treasure and pleasure
No full textThis Microreview seeks to highlight the molecular diversity present in marine organisms, and illustrate by example some of the challenges encountered in exploring this resource. Marine natural products exhibit an impressive array of structural motifs, many of which are derived from biosynthetic pathways that are uniquely marine, Most importantly some marine metabolites possess noteworthy biological activities, activities that have potential application outside marine ecosystems, such as antibiotics, antiparasitics, anticancer agents etc... The isolation, spectroscopic characterisation and assignment of stereostructures to these unusual metabolites is both challenging and rewarding. Examples featured in this Microreview follow a common theme in that they are all recent accounts of the isolation of natural products from Australian marine sponges, carried out in the laboratories of the author. In addition to presenting brief comments on specific structure elucidation strategies, an effort is made to emphasize techniques for solving stereochemical issues, as well as to speculate on the biosynthetic origins of some of these exotic marine natural products
LE INFORMAZIONI ESTRAIBILI DAL DATO LASER SCANNER PER LO STUDIO DI EDIFICI STORICI
No full textLa disciplina del restauro costituisce un ponte di collegamento fra le materie di carattere umanistico e quelle
di carattere tecnico che si integrano le une alle altre nell’obiettivo comune di perpetuare i valori storici e
architettonici di cui il monumento è depositario. Uno studio completo non può che essere effettuato mediante
l’applicazione e l’integrazione di una vasta gamma di tecniche di rilievo, distruttive e non, mirate all’analisi
delle strutture, allo studio dei terreni di fondazione e del suolo, senza tralasciare la valutazione degli effetti
ambientali. Coniugando la tecnica avanzata del rilievo eseguito con il laser scanner con le indagini tematiche
che si sviluppano attraverso la lettura stratigrafi ca verticale si conseguono risultati importanti per comprendere
la complessità storico-costruttiva del monumento e quindi utili per il progetto di conservazione.Published12-161.10. TTC - TelerilevamentoN/A or not JCRreserve
Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells
No full textChronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. Current targeted therapies designed to inhibit the tyrosine kinase activity of the BCR-ABL oncoprotein have made a significant breakthrough in the treatment of CML patients. However, CML remains a chronic disease that a patient must manage for life. Although tyrosine kinase inhibitors (TKI) therapy has completely transformed the prognosis of CML, it has made the therapeutic management more complex. The interruption of TKI treatment results in early disease progression because it does not eliminate quiescent CML stem cells which remain a potential reservoir for disease relapse. This highlights the need to develop new therapeutic strategies for CML to achieve a permanent cure, and to allow TKI interruption. This review summarizes recent research done on alternative targeted therapies with a particular focus on some important signaling pathways (such as Alox5, Hedgehog, Wnt-b-catenin, autophagy, and PML) that have the potential to target CML stem cells and potentially provide cure for CML. © 2013 Ahmad Hamad et al.Assouline S, 2011, CURR ONCOL, V18, pE71; Babashah S, 2013, INT J CANCER, V133, P579, DOI 10.1002-ijc.28043; Baccarani M, 2009, J CLIN ONCOL, V27, P6041, DOI 10.1200-JCO.2009.25.0779; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172-JCI35660; Bixby D., 2009, ASH ED PROGRAM BOOK, P461; Brixey AG, 2010, CURR OPIN PULM MED, V16, P351, DOI 10.1097-MCP.0b013e328338c486; Calabretta B, 2011, LEUKEMIA LYMPHOMA, V52, P54, DOI 10.3109-10428194.2010.546913; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182-blood-2003-12-4111; Castagnetti F, 2009, BLOOD, V113, P3428, DOI 10.1182-blood-2007-08-103499; Chen Y, 2010, LEUKEMIA, V24, P1545, DOI 10.1038-leu.2010.143; Chen YY, 2009, NAT GENET, V41, P783, DOI 10.1038-ng.389; Chen YY, 2010, PROTEIN CELL, V1, P124, DOI 10.1007-s13238-010-0016-z; Cohen MH, 2002, CLIN CANCER RES, V8, P935; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182-blood-2005-07-2947; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172-JCI35721; Cortes J, 2012, J NATL COMPR CANC NE, V10, pS1; Cortes JE, 2012, J CLIN ONCOL, V30, P3486, DOI 10.1200-JCO.2011.38.7522; Cortes JE, 2012, NEW ENGL J MED, V367, P2075, DOI 10.1056-NEJMoa1205127; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016-j.ccr.2008.08.003; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038-nm0596-561; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038-nature07815; Fereshteha M, 2012, P NATL ACAD SCI USA, V109, P12532, DOI 10.1073-pnas.1209815109; Goldman JM, 2009, J CLIN ONCOL, V27, P313, DOI 10.1200-JCO.2008.19.2260; Goldman JM, 2007, BLOOD, V110, P2828, DOI 10.1182-blood-2007-04-038943; Goldman JM, 2010, SEMIN HEMATOL, V47, P302, DOI [10.1053-j.seminhematol.2010.07.001, 10.1053-j.seminhemato1.2010.07.001]; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126-science.1062538; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182-blood.V99.1.319; Gupta Aman, 2013, Recent Pat Endocr Metab Immune Drug Discov, V7, P138; Hantschel O, 2012, NAT CHEM BIOL, V8, P285, DOI [10.1038-nchembio.775, 10.1038-NCHEMBIO.775]; Helgason GV, 2011, BLOOD, V118, P2035, DOI 10.1182-blood-2011-01-330621; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038-sj.leu.2402741; Hu Y, 2009, LEUKEMIA, V23, P109, DOI 10.1038-leu.2008.262; Hughes TP, 2010, BLOOD, V116, P3758, DOI 10.1182-blood-2010-03-273979; Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084-jem.20110304; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038-nature07016; Jabbour E, 2009, MAYO CLIN PROC, V84, P161, DOI 10.1016-S0025-6196(11)60824-0; Jagani Z, 2009, CANCER RES, V69, P6546, DOI 10.1158-0008-5472.CAN-09-0605; Jagani Z, 2010, CELL CYCLE, V9, P3449, DOI 10.4161-cc.9.17.12945; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056-NEJMoa040258; Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056-NEJMoa1002315; Keller-von Amsberg G, 2012, EXPERT REV ANTICANC, V12, P1121, DOI [10.1586-era.12.84, 10.1586-ERA.12.84]; Li L, 2012, CANCER CELL, V21, P266, DOI 10.1016-j.ccr.2011.12.020; Liao HF, 2012, BIOMED PHARMACOTHER, V66, P378, DOI 10.1016-j.biopha.2011.12.008; Long B., 2011, J EXPT CLIN CANC RES, V30; Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174-1568009043332709; Mahon FX, 2010, LANCET ONCOL, V11, P1029, DOI 10.1016-S1470-2045(10)70233-3; Mar BG, 2011, LEUKEMIA, V25, P1665, DOI 10.1038-leu.2011.143; Muller MC, 2009, BLOOD, V114, P4944, DOI 10.1182-blood-2009-04-214221; Naka K, 2010, NATURE, V463, P676, DOI 10.1038-nature08734; Nasr R, 2012, PATHOL BIOL, V60, P239, DOI 10.1016-j.patbio.2012.05.010; Nestal de Moraes G, 2012, LEUKEMIA RES TREATME, V2012; Nicholson E., 2009, CLIN LYMPHOMA MYE S4, V9, P376; NOWELL PC, 1960, J NATL CANCER I, V25, P85; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056-NEJMoa022457; Ohanian M, 2012, EXPERT OPIN PHARMACO, V13, P927, DOI 10.1517-14656566.2012.672974; O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016-j.ccr.2009.09.028; O'Hare T, 2012, NAT REV CANCER, V12, P513, DOI 10.1038-nrc3317; O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182-blood-2007-03-066936; Preudhomme C, 2010, NEW ENGL J MED, V363, P2511, DOI 10.1056-NEJMoa1004095; Puttini M, 2006, CANCER RES, V66, P11314, DOI 10.1158-0008-5472.CAN-06-1199; Radmark O, 2010, BIOCHEM BIOPH RES CO, V396, P105, DOI 10.1016-j.bbrc.2010.02.173; Ray A, 2007, BLOOD, V109, P5011, DOI 10.1182-blood-2006-01-015347; Report of the Medical Research Council's working party for therapeutic trials in leukemia, 1968, BRIT MED J, V1, P201; Rohrbacher M, 2009, BEST PRACT RES CL HA, V22, P295, DOI 10.1016-j.beha.2009.07.007; Rosti G, 2009, BLOOD, V114, P4933, DOI 10.1182-blood-2009-07-232595; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038-243290a0; Saglio G, 2010, NEW ENGL J MED, V362, P2251, DOI 10.1056-NEJMoa0912614; Samanta A, 2011, LEUKEMIA, V25, P463, DOI 10.1038-leu.2010.287; Samanta AK, 2006, CANCER RES, V66, P6468, DOI 10.1158-0008-5472.CAN-06-0025; Santos FPS, 2011, CANCER J, V17, P465, DOI 10.1097-PPO.0b013e31823dec8d; Schurch C, 2012, J CLIN INVEST, V122, P624, DOI 10.1172-JCI45977; Su WX, 2012, EXP HEMATOL, V40, P418, DOI 10.1016-j.exphem.2012.01.003; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182-blood-2011-12-397554; Wang XZ, 2011, DNA CELL BIOL, V30, P71, DOI 10.1089-dna.2010.1112; Willis SG, 2005, BLOOD, V106, P2128, DOI 10.1182-blood-2005-03-1036; Wisniewski D, 2011, BLOOD CANCER J, V1, DOI 10.1038-bcj.2011.35; Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038-leu.2012.65; Yuan HF, 2012, BLOOD, V119, P1904, DOI 10.1182-blood-2011-06-361691; Zhang HJ, 2012, MOL CELL BIOL, V32, P1776, DOI 10.1128-MCB.05672-11; Zhang HJ, 2013, PROTEIN CELL, V4, P186, DOI 10.1007-s13238-013-2115-0; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016-j.ccr.2007.11.003; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038-nature0773732
Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012
No full text[No abstract available]345367382Baccarani, M., Dreyling, M., Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up (2009) Ann Oncol, 20 (4 SUPPL.), pp. 105-107. , ESMO Guidelines Working GroupVardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes (2009) Blood, 114 (5), pp. 937-951. , Comment in: Blood. 2010;115(3):748-9author reply 749-50Tefferi, A., Vardiman, J.W., Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms (2008) Leukemia, 22 (1), pp. 14-22. , Comment in: Leukemia. 2008;22(11):2118-9Verma, D., Kantarjian, H.M., Jones, D., Luthra, R., Borthakur, G., Verstovsek, S., Chronic myeloid leukemia (CML) with P190 BCR-ABL: Analysis of characteristics, outcomes, and prognostic significance (2009) Blood, 114 (11), pp. 2232-2235Lucas, C.M., Harris, R.J., Giannoudis, A., Davies, A., Knight, K., Watmough, S.J., Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript (2009) Haematologica, 94 (10), pp. 1362-1367. , Comment in: Haematologica. 2010;95(5):852-3de Lemos, J.A., de Oliveira, C.M., Scerni, A.C., Bentes, A.Q., Beltrão, A.C., Bentes, I.R., Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia (2005) Genet Mol Res, 4 (4), pp. 803-811Sharma, P., Kumar, L., Mohanty, S., Kochupillai, V., Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts (2010) Ann Hematol, 89 (3), pp. 241-247Kreil, S., Pfirrmann, M., Haferlach, C., Waghorn, K., Chase, A., Hehlmann, R., Reiter, A., Cross, N.C., Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia (2007) Blood, 110 (4), pp. 1283-1290. , German Chronic Myelogenous Leukemia (CML) Study GroupGhaith, F., Abdou, S., El-Bendary, A., Shahin, D., Eid, M., Megeed, W.A., Prognostic relevance of 9q34 deletion and the suppressor of cytokine signalling-1 in CML patients (2010) Int J Lab Hematol, 32 (1 PART 2), pp. 103-112Cohen, N., Rozenfeld-Granot, G., Hardan, I., Brok-Simoni, F., Amariglio, N., Rechavi, G., Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: Expression profiling, resistance to interferon therapy, and poor prognosis (2001) Cancer Genet Cytogenet, 128, pp. 114-119Quintas-Cardama, A., Kantarjian, H., Talpaz, M., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia (2005) Blood, 105 (6), pp. 2281-2286Quintás-Cardama, A., Kantarjian, H., Shan, J., Jabbour, E., Abruzzo, L.V., Verstovsek, S., Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib (2011) Cancer, 117 (22), pp. 5085-5093Huntly, B.J., Reid, A.G., Bench, A.J., Campbell, L.J., Telford, N., Shepherd, P., Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia (2001) Blood, 98 (6), pp. 1732-1738. , Comment in: Blood. 2001;98(9):2879-80Fourouclas, N., Campbell, P.J., Bench, A.J., Swanton, S., Baxter, E.J., Huntly, B.J., Size matters: The prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia (2006) Haematologica, 91 (7), pp. 952-955Lee, Y.K., Kim, Y.R., Min, H.C., Oh, B.R., Kim, T.Y., Kim, Y.S., Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia (2006) Cancer Genet Cytogenet, 166 (1), pp. 65-73Vaz de Campos, M.G., Montesano, F.T., Rodrigues, M.M., Chauffaille, M.L., Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia (2007) Cancer Genet Cytogenet, 178 (1), pp. 49-56Marzocchi, G., Castagnetti, F., Luatti, S., Baldazzi, C., Stacchini, M., Gugliotta, G., Amabile, M., Testoni, N., Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis (2011) Blood, 117 (25), pp. 6793-6800. , Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid LeukemiaCastagnetti, F., Testoni, N., Luatti, S., Marzocchi, G., Mancini, M., Kerim, S., Giugliano, E., Rosti, G., Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis (2010) J Clin Oncol, 28 (16), pp. 2748-2754Landstrom, A.P., Knudson, R.A., Dewald, G.W., Ketterling, R.P., Tefferi, A., Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: Clinical correlates and effect on imatinib mesylate treatment outcome (2007) Leuk Lymphoma, 48 (11), pp. 2137-2140Gorusu, M., Benn, P., Li, Z., Fang, M., On the genesis and prognosis of variant translocations in chronic myeloid leukemia (2007) Cancer Genet Cytogenet, 173 (2), pp. 97-106Meggyesi, N., Kozma, A., Halm, G., Nahajevszky, S., Bátai, A., Fekete, S., Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients (2012) Acta Haematol, 127 (1), pp. 34-42Kim, T.D., Türkmen, S., Schwarz, M., Koca, G., Nogai, H., Bommer, C., Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia (2010) Hematologica, 95 (4), pp. 582-588Haus, O., Noworolska, A., Laskowski, M., Kuliszkiewicz-Janus, M., Kozlowska, J., Harlozinska-Szmyrka, A., Prognostic significance of secondary cytogenetic changes and nonspecific cross-reacting antigen (NCA) in patients with Ph-positive chronic myeloid leukemia (1990) Exp Mol Pathol, 52 (2), pp. 235-242Hsiao, H.H., Liu, Y.C., Tsai, H.J., Hsu, J.F., Yang, W.C., Chang, C.S., Additional chromosome abnormalities in chronic myeloid leukemia (2011) Kaohsiung J Med Sci, 2 (27), pp. 49-54Vranová, V., Katina, S., Kirschnerová, G., Mistrík, M., Lakota, J., Horáková, J., A significance of additional chromosomal aberrations and other variables on post transplantation outcome of patients with CML (2005) Neoplasma, 52 (5), pp. 381-387Fabarius, A., Leitner, A., Hochhaus, A., Müller, M.C., Hanfstein, B., Haferlach, C., Göhring, G., Hehlmann, R., Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV (2011) Blood, 118 (26), pp. 6760-6768. , Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study GroupAhmed, R., Naqi, N., Hussain, I., Khattak, B.K., Nadeem, M., Iqbal, J., Presentating phases of chronic myeloid leukaemia (2009) J Coll Physicians Surg Pak, 19 (8), pp. 469-472Cortes, J., Kantarjian, H., Advanced-phase chronic myeloid leukemia (2003) Semin Hematol, 40 (1), pp. 79-86Cortes, J.E., Talpaz, M., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Staging of chronic myeloid leukemia in the imatinib era: An evaluation of the World Health Organization proposal (2006) Cancer, 106 (6), pp. 1306-1315Cortes, J., Natural history and staging of chronic myelogenous leukemia (2004) Hematol Oncol Clin North Am, 18 (3), pp. 569-84+8Aguayo, A., Couban, S., State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: Evolutionary trends in diagnosis, monitoring and treatment (2009) Leuk Lymphoma, 50 (2 SUPPL.), pp. 1-8O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J.J., Druker, B.J., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia (2003) N Engl J Med, 348 (11), pp. 994-1004. , IRIS InvestigatorsBonifazi, F., de Vivo, A., Rosti, G., Tiribelli, M., Russo, D., Trabacchi, E., Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon (2000) Br J Haematol, 111 (2), pp. 587-595. , Italian Cooperative Study Group on Chronic Myeloid LeukaemiaCorm, S., Roche, L., Micol, J.B., Coiteux, V., Bossard, N., Nicolini, F.E., Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: A population study (2011) Blood, 118 (16), pp. 4331-4337Druker, B.J., Guilhot, F., O'Brien, S.G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M.W., Larson, R.A., Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2006) N Engl J Med, 355 (23), pp. 2408-2417. , IRIS InvestigatorsDeenik, W., Janssen, J.J., van der Holt, B., Verhoef, G.E., Smit, W.M., Kersten, M.J., Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia (2010) Haematologica, 95 (6), pp. 914-921Forrest, D.L., Trainor, S., Brinkman, R.R., Barnett, M.J., Hogge, D.E., Nevill, T.J., Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels (2009) Leuk Res, 33 (2), pp. 271-275. , Comment in: Leuk Res. 2009;33(8):1147-8author reply 1149-50Hasford, J., Pfirrmann, M., Hehlmann, R., Baccarani, M., Guilhot, F., Mahon, F.X., Kluin-Nelemans, H.C., Steegmann, J.L., Prognosis and prognostic factors for patients with chronic myeloid leukemia: Nontransplant therapy (2003) Semin Hematol, 40 (1), pp. 4-12. , Collaborative CML Prognostic Factors Project GroupRajappa, S., Varadpande, L., Paul, T., Jacob, R., Digumarti, R., Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience From a Developing Country (2008) Leuk Lymphoma, 49 (3), pp. 554-558Lee, J.P., Birnstein, E., Masiello, D., Yang, D., Yang, A.S., Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: A single-institution retrospective study (2009) J Hematol Oncol, 2, p. 30Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (2010) N Engl J Med, 362 (24), pp. 2260-2270. , Comment in: N Engl J Med. 2010;362(24):2314-5. N Engl J Med. 2010;363(17):1672- 3author reply 1673-5. Expert Opin Pharmacother. 2011;12(1):157-63. N Engl J Med. 2010;363(17):1673;author reply 1673-5Kantarjian, H.M., Shah, N.P., Cortes, J.E., Baccarani, M., Agarwal, M.B., Undurraga, M.S., Dasatinib or imatinib in newly diagnosed chronicphase chronic myeloid leukemia: 2 year follow-up from a randomized phase 3 trial (DASISION) (2012) Blood, 119 (5), pp. 1123-1129Saglio, G., Kim, D.W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Kantarjian, H.M., Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (2010) N Engl J Med, 362 (24), pp. 2251-2259. , ENESTnd Investigators, Comment in: N Engl J Med. 2010;362(24):2314-5N Engl J Med. 2010;363(17):1672author reply 1673-5Expert Opin Pharmacother. 2011;12(1):157-63N Engl J Med. 2010;363(17):1673author reply 1673-5Kantarjian, H.M., Hochhaus, A., Saglio, G., de Souza, C., Flinn, I.W., Stenke, L., Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial (2011) Lancet Oncol, 12 (9), pp. 841-851. , Comment in: Lancet Oncol. 2011;12(9):826-7Breccia, M., Stefanizzi, C., Cannella, L., Latagliata, R., Frustaci, A.M., Carmosino, I., Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia (2008) Leuk Lymphoma, 49 (12), pp. 2328-2332Scerni, A.C., Alvares, L.A., Beltrão, A.C., Bentes, I.R., Azevedo, T.C., Bentes, A.Q., Influence of late treatment on how chronic myeloid leukemia responds to imatinib (2009) Clinics (Sao Paulo), 64 (8), pp. 731-734Cortes, J.E., Talpaz, M., Giles, F., O'Brien, S., Rios, M.B., Shan, J., Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy (2003) Blood, 101 (10), pp. 3794-3800Kantarjian, H.M., Cortes, J.E., O'Brien, S., Luthra, R., Giles, F., Verstovsek, S., Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha (2004) Blood, 104 (7), pp. 1979-1988Palandri, F., Iacobucci, I., Martinelli, G., Amabile, M., Poerio, A., Testoni, N., Soverini, S., Baccarani, M., Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: The GIMEMA Working Party on CML (2008) J Clin Oncol, 26 (1), pp. 106-111. , GIMEMA Working Party on CMLGambacorti-Passerini, C., Antolini, L., Mahon, F.X., Guilhot, F., Deininger, M., Fava, C., Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib (2011) J Natl Cancer Inst, 103 (7), pp. 553-561. , Comment in: J Natl Cancer Inst. 2011;103(7):527-9Fava, C., Kantarjian, H.M., Jabbour, E., O'Brien, S., Jain, N., Rios, M.B., Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase (2009) Blood, 113 (21), pp. 5058-5063Milojkovic, D., Nicholson, E., Apperley, J.F., Holyoake, T.L., Shepherd, P., Drummond, M.W., Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia (2010) Haematologica, 95 (2), pp. 224-231Marin, D., Kaeda, J., Szydlo, R., Saunders, S., Fleming, A., Howard, J., Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: Patterns of residual leukaemia and prognostic factors for cytogenetic relapse (2005) Leukemia, 19 (4), pp. 507-512Furukawa, T., Narita, M., Koike, T., Takai, K., Nagai, K., Kobayashi, M., Koyama, S., Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: Results of the Niigata CML-multi-institutional co-operative clinical study (2011) Int J Hematol, 93 (3), pp. 336-343Cortes, J.E., Kantarjian, H.M., Goldberg, S.L., Powell, B.L., Giles, F.J., Wetzler, M., Akard, L., Radich, J., High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses (2009) J Clin Oncol, 27 (28), pp. 4754-4759. , Rationale and Insight for Gleevec High-Dose, Therapy (RIGHT) Trial Study GroupRoss, D.M., Branford, S., Moore, S., Hughes, T.P., Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL (2006) Leukemia, 20 (4), pp. 664-670Press, R.D., Galderisi, C., Yang, R., Rempfer, C., Willis, S.G., Mauro, M.J., A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response (2007) Clin Cancer Res, 13 (20), pp. 6136-6143Lange, T., Bumm, T., Otto, S., Al-Ali, H.K., Kovacs, I., Krug, D., Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy (2004) Haematologica, 89 (1), pp. 49-57. , Comment in: Haematologica. 200489(1):6-9Lima, L., Bernal-Mizrachi, L., Saxe, D., Mann, K.P., Tighiouart, M., Arellano, M., Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond (2011) Cancer, 117 (6), pp. 1245-1252Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial (2007) Blood, 109 (12), pp. 5143-5150Kantarjian, H., Pasquini, R., Lévy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R) (2009) Cancer, 115 (18), pp. 4136-4147Shah, N.P., Kantarjian, H.M., Kim, D.W., Réa, D., Dorlhiac-Llacer, P.E., Milone, J.H., Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib- resistant and-intolerant chronic-phase chronic myeloid leukemia (2008) J ClinOncol, 26 (19), pp. 3204-3212. , Comment in: Nat Clin Pract Oncol. 2009;6(2):68-9Shah, N.P., Kim, D.W., Kantarjian, H., Rousselot, P., Llacer, P.E., Enrico, A., Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimalresponse or intolerance to imatinib (2010) Haematologica, 95 (2), pp. 232-240Koren-Michowitz, M., le Coutre, P., Duyster, J., Scheid, C., Panayiotidis, P., Prejzner, W., Activity and tolerability of nilotinib: A retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant (2010) Cancer, 116 (19), pp. 4564-4572Kantarjian, H.M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Nilotinib (formerlyAMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective inpatients with Philadelphia chromosome- positive chronic myelogenous leukemia inchronic phase following imatinib resistance and intolerance (2007) Blood, 110 (10), pp. 3540-3546Kantarjian, H.M., Giles, F.J., Bhalla, K.N., Pinilla-Ibarz, J., Larson, R.A., Gattermann, N., Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase afterimatinib resistance or intolerance: 24-month follow-up results (2011) Blood, 117 (4), pp. 1141-1145Giles, F.J., Abruzzese, E., Rosti, G., Kim, D.W., Bhatia, R., Bosly, A., Nilotinib is active in chronic and accelerated phase chronic myeloid leukemiafollowing failure of imatiniband dasatinib therapy (2010) Leukemia, 24 (7), pp. 1299-1301Khoury, H.J., Cortes, J.E., Kantarjian, H.M., Gambacorti-Passerini, C., Baccarani, M., Kim, D.W., Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure (2012) Blood, 119 (15), pp. 3403-3412Noens, L., van Lierde, M.A., de Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., Abraham, I., Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study (2009) Blood, 113 (22), pp. 5401-5411Marin, D., Bazeos, A., Mahon, F.X., Eliasson, L., Milojkovic, D., Bua, M., Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib (2010) J Clin Oncol, 28 (14), pp. 2381-2388Ibrahim, A.R., Eliasson, L., Apperley, J.F., Milojkovic, D., Bua, M., Szydlo, R., Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy (2011) Blood, 117 (14), pp. 3733-3736Ganesan, P., Sagar, T.G., Dubashi, B., Rajendranath, R., Kannan, K., Cyriac, S., Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia (2011) Am J Hematol, 86 (6), pp. 471-474Jabbour, E., Kantarjian, H., O'Brien, S., Shan, J., Garcia-Manero, G., Wierda, W., Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure (2011) Blood, 117 (6), pp. 1822-1827. , Comment in: Blood. 2011117(6):1773-4Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis (2003) Blood, 102 (1), pp. 276-283Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA Working Party on Chronic Myeloid Leukemia (2005) J Clin Oncol, 23 (18), pp. 4100-4109Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S., Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate (2006) Leukemia, 20 (10), pp. 1767-1
